Aqueous humor monocyte chemoattractant protein-1 predicted long-term visual outcome of proliferative diabetic retinopathy undergone intravitreal injection of bevacizumab and vitrectomy
Open Access
- 5 March 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3), e0248235
- https://doi.org/10.1371/journal.pone.0248235
Abstract
We aim to investigate the risk factors associated with the prognosis of proliferative diabetic retinopathy (PDR) after a sequential treatment of intravitreal injection of bevacizumab (IVB) and pars plana vitrectomy (PPV). In this cohort study, 63 eyes from 55 patients (21 females) diagnosed with PDR, who needed PPV for non-clearing vitreous hemorrhage or fibrovascular membrane proliferation were enrolled. All the eyes underwent IVB followed by PPV. Anterior chamber tap was performed at the beginning of both procedures to evaluate the concentration of vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, and monocyte chemoattractant protein (MCP)-1. Forty-seven patients (54 eyes) were followed over six months, averaging 12±5 (6–19) months. The concentration of VEGF significantly decreased after IVB (P<0.001), while other cytokines did not change significantly. The aqueous humor level of IL-8 after IVB (R = 0.378, P = 0.033), MCP-1 before (R = 0.368, P = 0.021) and after (R = 0.368, P = 0.038) IVB, and combined phacoemulsification (R = 0.293, P = 0.032) was correlated with the logMAR visual acuity at the last follow-up. Multivariate analysis showed that MCP-1 was the predictor for a worse visual outcome (B = 0.108, 95% CI 0.013–0.202; P = 0.027). MCP-1 was a predictor for the unfavorable visual outcome of PDR after IVB pretreatment and PPV.Keywords
Funding Information
- Institutional Foundation of The First Affiliated Hospital of Xi'an Jiaotong University (2013YK41)
This publication has 24 references indexed in Scilit:
- Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic RetinopathyOphthalmology, 2018
- Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trialsBritish Journal of Ophthalmology, 2017
- Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval VariationAmerican Journal of Ophthalmology, 2017
- Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathyClinical Ophthalmology, 2017
- Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedemaBritish Journal of Ophthalmology, 2015
- EFFECTS OF INTRAVITREAL INJECTION OF BEVACIZUMAB ON INFLAMMATORY CYTOKINES IN THE VITREOUS WITH PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2014
- Intraocular VEGF Level as a Risk Factor for Postoperative Complications after Vitrectomy for Proliferative Diabetic RetinopathyInvestigative Opthalmology & Visual Science, 2012
- Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokinesEye, 2006
- Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin IIBritish Journal of Ophthalmology, 2004
- Complications of Vitreous Surgery for Diabetic RetinopathyOphthalmology, 1983